DexCom (MIL:1DXCM) Cyclically Adjusted Revenue per Share: €5.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1DXCM DexCom Inc MIL:1DXCM
72 GF Score
Price €60.60
GF Value €85.28
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom Cyclically Adjusted Revenue per Share?

DexCom MIL:1DXCM 72 Cyclically Adjusted Revenue per Share is €5.93 as of Mar. 2026. GuruFocus rates MIL:1DXCM with a GF Score™ of 72/100 and a GF Value™ of €85.28 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DexCom's adjusted revenue per share for the three months ended in Mar. 2026 was €2.619. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, DexCom's average Cyclically Adjusted Revenue Growth Rate was 21.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 23.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 26.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 32.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of DexCom was 39.20% per year. The lowest was 23.20% per year. And the median was 35.25% per year.

As of today (2026-07-15), DexCom's current stock price is €60.60. DexCom's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €5.93. DexCom's Cyclically Adjusted PS Ratio of today is 10.22.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 65.27. The lowest was 8.79. And the median was 29.80.


DexCom  (MIL:1DXCM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

DexCom's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=60.60/5.93
=10.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 65.27. The lowest was 8.79. And the median was 29.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DexCom Cyclically Adjusted Revenue per Share Related Terms


DexCom Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for DexCom's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Cyclically Adjusted Revenue per Share Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.60

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.19 5.44 5.60 5.93

MIL:1DXCM vs GEHC, STE, ZBH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, DexCom's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DexCom's Cyclically Adjusted PS Ratio falls into.


MIL:1DXCM
72GF Score
DexCom Inc MIL:1DXCM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DexCom's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.619/330.2130*330.2130
=2.619

Current CPI (Mar. 2026) = 330.2130.

DexCom Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.365 241.018 0.500
201609 0.394 241.428 0.539
201612 0.480 241.432 0.657
201703 0.390 243.801 0.528
201706 0.434 244.955 0.585
201709 0.447 246.819 0.598
201712 0.537 246.524 0.719
201803 0.428 249.554 0.566
201806 0.580 251.989 0.760
201809 0.633 252.439 0.828
201812 0.836 251.233 1.099
201903 0.687 254.202 0.892
201906 0.817 256.143 1.053
201909 0.973 256.759 1.251
201912 1.125 256.974 1.446
202003 0.974 258.115 1.246
202006 1.034 257.797 1.324
202009 1.069 260.280 1.356
202012 1.177 260.474 1.492
202103 1.014 264.877 1.264
202106 1.156 271.696 1.405
202109 1.284 274.310 1.546
202112 1.432 278.802 1.696
202203 1.332 287.504 1.530
202206 1.563 296.311 1.742
202209 1.825 296.808 2.030
202212 1.806 296.797 2.009
202303 1.655 301.836 1.811
202306 1.864 305.109 2.017
202309 2.141 307.789 2.297
202312 2.274 306.746 2.448
202403 2.033 312.332 2.149
202406 2.238 314.175 2.352
202409 2.184 315.301 2.287
202412 2.615 315.605 2.736
202503 2.352 319.799 2.429
202506 2.458 322.561 2.516
202509 2.529 324.800 2.571
202512 2.697 324.054 2.748
202603 2.619 330.213 2.619

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €5.93 mean?
DexCom (MIL:1DXCM) has a Cyclically Adjusted Revenue per Share of €5.93 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DexCom and its competitors.
Is DexCom's Cyclically Adjusted Revenue per Share too high?
DexCom's current Cyclically Adjusted Revenue per Share is €5.93. Overall, DexCom has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Cyclically Adjusted Revenue per Share compare to GEHC and STE?
DexCom's Cyclically Adjusted Revenue per Share of €5.93 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DexCom and its competitors. DexCom's current Cyclically Adjusted Revenue per Share is €5.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (MIL:1DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.28, compared to a current price of €60.60 — trading 28.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €5.93. DexCom's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For DexCom (MIL:1DXCM), the current Cyclically Adjusted Revenue per Share is €5.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (MIL:1DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of €60.60 is trading 28.9% below its estimated GF Value™ of €85.28. GuruFocus considers DexCom to be Modestly Undervalued.

Key valuation signals for MIL:1DXCM:

  • Cyclically Adjusted Revenue per Share: €5.93
  • GF Value™: €85.28 vs. price of €60.60 (28.9% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the MIL:1DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
72GF Score

Get the complete analysis for MIL:1DXCM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.60
Price
€85.28
GF Value